Literature DB >> 7512810

Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer.

J S Falconer1, K C Fearon, C E Plester, J A Ross, D C Carter.   

Abstract

OBJECTIVE: To determine whether resting energy expenditure (REE) is increased in cachectic patients with pancreatic cancer and to define the relation of tumor necrosis factor (TNF) and interleukin-6 (IL-6) production to the acute-phase response and to REE.
METHODS: Measurement of REE (indirect calorimetry) and assessment of body composition (bioelectrical impedance analysis) were done in 21 patients with unresectable pancreatic cancer and on 16 age-related controls. The systemic inflammatory response in peripheral blood of the cancer patients was assessed using the acute-phase protein, C-reactive protein, and the cytokines TNF and IL-6. Production of these cytokines by peripheral blood mononuclear cells in vitro was also measured.
RESULTS: Patients with pancreatic cancer had an elevated REE when compared with controls (73.4 +/- 5.0 vs. 53.5 +/- 1.6 kcal/kg body cell mass; p < 0.003). Resting energy expenditure was significantly greater in cancer patients with an acute-phase response (C-reactive protein > 10 mg/L) than in those who did not have such a response (85.5 +/- 10.0 [n = 9] vs. 64.3 +/- 3.0 [n = 12] kcal/kg body cell mass; p < 0.04). Tumor necrosis factor was not detected in the serum of any of the cancer patients. Serum IL-6 was detected but levels were not significantly different among cancer patients with or without an acute-phase response. In contrast, spontaneous production of TNF and IL-6 by isolated peripheral blood mononuclear cells was significantly greater in cancer patients with an acute-phase response that in those without (TNF: 1231 +/- 244 vs. 210 +/- 54 pg/ml/10(5) cells; p < 0.001; IL-6: 11.5 +/- 1.7 vs. 3.6 +/- 1.4 ng/mL/10(5) cells; p < 0.003).
CONCLUSIONS: In pancreatic cancer at least a component of weight loss is due to increased REE. Furthermore, the presence of an acute-phase response identifies a group of patients who are markedly hypermetabolic. The serum concentration of TNF of IL-6 does not correlate with the presence of an acute-phase response, whereas rates of cytokine production by peripheral blood mononuclear cells are significantly greater in patients with such a response. This suggests that local rather than systemic cytokine production may be important in regulating the acute-phase response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512810      PMCID: PMC1243147          DOI: 10.1097/00000658-199404000-00001

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  34 in total

1.  The relationship between resting energy expenditure and weight loss in benign and malignant disease.

Authors:  D T Hansell; J W Davies; H J Burns
Journal:  Ann Surg       Date:  1986-03       Impact factor: 12.969

2.  Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer.

Authors:  K C Fearon; D T Hansell; T Preston; J A Plumb; J Davies; D Shapiro; A Shenkin; K C Calman; H J Burns
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

3.  Resting energy expenditure and body cell mass alterations in noncachectic patients with sarcomas.

Authors:  J L Peacock; R I Inculet; R Corsey; D B Ford; W F Rumble; D Lawson; J A Norton
Journal:  Surgery       Date:  1987-09       Impact factor: 3.982

4.  Cancer cachexia and protein metabolism.

Authors:  M Jeevanandam; G D Horowitz; S F Lowry; M F Brennan
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

Review 5.  Interleukin 1, tumour necrosis factor-alpha (cachectin) and the pathogenesis of cancer cachexia.

Authors:  L L Moldawer; M Georgieff; K Lundholm
Journal:  Clin Physiol       Date:  1987-08

6.  Tumors secreting human TNF/cachectin induce cachexia in mice.

Authors:  A Oliff; D Defeo-Jones; M Boyer; D Martinez; D Kiefer; G Vuocolo; A Wolfe; S H Socher
Journal:  Cell       Date:  1987-08-14       Impact factor: 41.582

7.  Induction of rat acute-phase proteins by interleukin 6 in vivo.

Authors:  T Geiger; T Andus; J Klapproth; T Hirano; T Kishimoto; P C Heinrich
Journal:  Eur J Immunol       Date:  1988-05       Impact factor: 5.532

8.  Elevated energy expenditure in cancer patients with solid tumours.

Authors:  A Hyltander; C Drott; U Körner; R Sandström; K Lundholm
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.

Authors:  K J Tracey; H Wei; K R Manogue; Y Fong; D G Hesse; H T Nguyen; G C Kuo; B Beutler; R S Cotran; A Cerami
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Tumour necrosis factor in man: clinical and biological observations.

Authors:  P Selby; S Hobbs; C Viner; E Jackson; A Jones; D Newell; A H Calvert; T McElwain; K Fearon; J Humphreys
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

View more
  90 in total

1.  Immunohistochemical and quantitative mRNA assessment of ghrelin expression in gastric and oesophageal adenocarcinoma.

Authors:  Marcus Mottershead; Emmanuel Karteris; Jill Y Barclay; Saira Suortamo; Mark Newbold; Harpal Randeva; Chuka U Nwokolo
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

2.  Inflammatory mediators in patients receiving long-term home parenteral nutrition.

Authors:  P R Ling; L Khaodhiar; B R Bistrian; M Keane-Ellison; A Thibault; N Tawa
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

3.  Pro-inflammatory cytokine release and mediation of the acute phase protein response in fulminant hepatic failure.

Authors:  S J Wigmore; T S Walsh; A Lee; J A Ross
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

4.  Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Dig Dis Sci       Date:  2008-07-26       Impact factor: 3.199

Review 5.  Obesity, pancreatitis, and pancreatic cancer.

Authors:  Andrew A Gumbs
Journal:  Obes Surg       Date:  2008-06-19       Impact factor: 4.129

6.  Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease.

Authors:  Christina Wu; Soledad A Fernandez; Tamara Criswell; Tarek A Chidiac; Denis Guttridge; Miguel Villalona-Calero; Tanios S Bekaii-Saab
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

Review 7.  Remodeling of the immunoinflammatory network system in elderly cancer patients: implications of inflamm-aging and tumor-specific hyperinflammation.

Authors:  Chikao Miki; Masato Kusunoki; Yasuhiro Inoue; Keiichi Uchida; Yasuhiko Mohri; John A C Buckels; Paul McMaster
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

Review 8.  Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review.

Authors:  William Paul Skelton; Hiral Parekh; Jason S Starr; Jose Trevino; Jessica Cioffi; Steven Hughes; Thomas J George
Journal:  J Gastrointest Cancer       Date:  2018-03

9.  The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer.

Authors:  D A C Deans; B H Tan; S J Wigmore; J A Ross; A C de Beaux; S Paterson-Brown; K C H Fearon
Journal:  Br J Cancer       Date:  2009-01-13       Impact factor: 7.640

10.  Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer.

Authors:  R J E Skipworth; D A C Deans; B H L Tan; K Sangster; S Paterson-Brown; D A Brown; M Hunter; S N Breit; J A Ross; K C H Fearon
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.